Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

137.79 -0.08 (-0.06%)
Streaming Delayed Price Updated: 1:05 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
News headline image
1 No-Brainer International Vanguard ETF to Buy Right Now for Less Than $100 ↗
A weakening dollar makes this ETF more appealing. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
2 High-Yielding ETFs That Can Bankroll Your Retirement for Years ↗
These funds offer yields that are more than three times the S&P 500 average. 
Via The Motley Fool
Topics ETFs Economy Retirement
News headline image
Why Novartis Stock Topped the Market Today ↗
The company has a brand-new product to ship to pharmacies. 
Via The Motley Fool
News headline image
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults ↗
Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements. 
Via Benzinga
Novartis Stock Softens Premarket Even As It Raises 2030 Outlook, Sales Guidance For Two Key Cancer Drugs ↗
Via Stocktwits
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗
Via Stocktwits
Topics Workforce
Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presence ↗
Via Stocktwits
News headline image
Novartis Stock Rises Premarket After FDA Approves First Gene Therapy For Teens And Adults With Muscle-Weakening Disorder ↗
FDA cleared Itvisma as the first gene-replacement therapy available to people 2 and older with the rare muscle-weakening condition. 
Via Stocktwits
News headline image
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Comprehensive Value Investment Analysis ↗
Novartis (NVS) appears undervalued with a low P/E ratio, strong profitability, and solid financial health, making it a compelling stock for value investors. 
Via Chartmill
News headline image
Bionique Wins Dual Golds for “Exosome + Probiotic” Breakthrough in Women’s Microbiome Health
Via Get News
News headline image
European Stocks Soar as Strong Earnings Quell 'AI Bubble' Fears
European equity markets have experienced a significant resurgence around November 20, 2025, with major indices climbing as robust company results, particularly from the technology sector, have... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗
Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030. 
Via Benzinga
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
Via Investor Brand Network
News headline image
Is the Market Bullish or Bearish on Novartis AG? ↗
 
Via Benzinga
News headline image
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗
AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
From BioMedWire
Via GlobeNewswire
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors ↗
Novartis (NVS) offers a strong 3.31% dividend yield with a history of reliable payouts and growth, backed by excellent profitability and financial health. 
Via Chartmill
News headline image
BIOCHINA2026 – Fusion Forward: Uniting the Global Biopharma Community in Suzhou
Via Press Release Distribution Service
News headline image
Trump Unveils $200 Billion Trade Deal With Switzerland And Liechtenstein To Cull $38.5 Billion US Goods Deficit By 2028 ↗
President Donald Trump announced a framework for a trade deal with Switzerland and Liechtenstein on Friday. 
Via Benzinga
Topics Government
News headline image
AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This... 
Via TokenRing AI
Topics Artificial Intelligence Economy Product Recall
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
BIOCHINA2026 – Fusion Forward: Uniting the Global Biopharma Community in Suzhou
Via Get News
News headline image
AI Revolutionizes Cardiovascular Clinical Trials: A Leap Towards Cheaper, Faster Drug Development
San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Novartis' Investigational Medicine Shows Potent Activity Against Drug-Resistant Malaria Strains ↗
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant parasite strains. 
Via Benzinga
News headline image
Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering
Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the... 
Via MarketMinute
Topics Initial Public Offering Intellectual Property Regulatory Compliance
News headline image
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
News headline image
Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. ↗
The company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534%. 
Via Investor's Business Daily
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades ↗
Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.